As previously reported, Piper Sandler initiated coverage of UroGen Pharma (URGN) with an Overweight rating and $36 price target Investors are starting to gain more confidence in the Zusduri launch, but the firm thinks the Street still underestimates peak sales potential in LG-IR-NMIBC and overestimates intellectual property risk to the -102/-103 franchise, the analyst contends. The firm sees early commercial launch datapoints, combined with updates from the Phase 3 UTOPIA trial of UGN-103, driving “meaningful upside” over the next 12-18 months.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on URGN:
- UroGen Pharma initiated with an Overweight at Piper Sandler
- UroGen Pharma’s Earnings Call: Achievements and Challenges
- UroGen Pharma price target lowered to $40 from $50 at H.C. Wainwright
- UroGen Pharma Reports Q2 2025 Results and Launches ZUSDURI
- Urogen Pharma’s Strategic Positioning and Growth Potential: Buy Rating Affirmed by Tara Bancroft